We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart ...

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...

Sanofi ( NASDAQ: SNY) has entered a share purchase agreement in relation to the sale of a 50% controlling stake in Opella, ...

Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

Sanofi's Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and Welfare for use in conjunction ...

Sanofi & Teva's IBD drug duvakitug shows promise in Phase 2b with €1B sales potential by 2032, faces competition from Roivant ...

Sanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...

Sanofi India's board has recommended a final dividend of ₹117 per equity share of ₹10 face value, subject to shareholder ...